Talkiatry and NOCD are teaming up to improve care for patients with obsessive-compulsive disorder. Talkiatry specializes in medication management, while NOCD specializes in Exposure and Response Prevention therapy.
The four companies are Alma, Headway, NOCD and Ophelia. Alma and Headway will help Empire expand its mental health provider network, while NOCD and Ophelia will address specific conditions: obsessive-compulsive disorder and opioid use disorder, respectively.
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
NOCD recently closed a $33 million funding round, led by F-Prime Capital. The startup plans to reach more people with OCD to offer exposure and response prevention therapy, a type of therapy that is considered an effective treatment for OCD, but can be difficult to find.
NOCD, a digital health company that connects users to therapists for OCD and self-help tools, has seen the number of people using its platform double since the Covid-19 pandemic started.